Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.50 | -$13.00 | -55.32% | 27.9M | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $5.96 | -$2.96 | -33.16% | 80.6K | $422M | $2.51$48.91 |
| FLYE | Fly-E Group | $2.52 | -$0.94 | -27.17% | 191.4K | $5.6M | $2.50$161.80 |
| PFSA | Profusa | $3.20 | -$1.17 | -26.82% | 192.6K | $378M | $3.16$957.00 |
| HIMS | Hims & Hers Health | $17.12 | -$5.90 | -25.63% | 2.4M | $5.2B | $16.36$72.98 |
| SMX | Smx (Security Matters) Public | $12.08 | -$3.75 | -23.69% | 2.6M | $138M | $3.12$9,134.28 |
| RDIB | Reading International | $10.37 | -$3.09 | -22.96% | 23.5K | $306M | $5.81$17.40 |
| MNDY | Monday.com | $76.88 | -$21.12 | -21.55% | 6.4M | $5.0B | $73.01$342.64 |
| SXTC | China Sxt Pharmaceuticals | $2.39 | -$0.61 | -20.33% | 4.2M | $2.6M | $2.34$1,176.00 |
| PGY | Pagaya Technologies | $14.93 | -$3.71 | -19.90% | 557.3K | $1.5B | $8.50$44.99 |
| VHUB | VenHub Global | $3.89 | -$0.94 | -19.46% | 225.9K | $362M | $3.86$40.30 |
| CLF | Cleveland-Cliffs | $11.87 | -$2.86 | -19.42% | 29.1M | $8.4B | $5.63$16.70 |
| MPAA | Motorcar Parts Of America | $10.76 | -$2.38 | -18.11% | 5.5K | $257M | $6.04$18.12 |
| ATLN | Atlantic International | $3.02 | -$0.43 | -12.46% | 29.4K | $216M | $1.16$6.50 |
| ALX | Alexander's | $224.27 | -$30.80 | -12.07% | 3.2K | $1.3B | $189.05$260.84 |
| CTEV | Claritev | $22.92 | -$2.99 | -11.54% | 64.2K | $428M | $12.86$74.07 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $33.93 | -$3.86 | -10.20% | 1.1M | - | $19.91$75.28 |
| ONEG | OneConstruction Group | $4.41 | -$0.50 | -10.18% | 789 | $79M | $1.00$13.50 |
| WSHP | WeShop | $40.24 | -$4.33 | -9.71% | 12.4K | $1.0B | $20.02$250.00 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
